Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma
Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma
复制标题
作者：
Sakata, K;Satoh, M;Himi, T
背景非霍奇金淋巴瘤（NHL）是一组异质性肿瘤，其生物学侵袭性和临床病程各不相同。在体外研究中，据报道基质金属蛋白酶9（MMP 9）由人NHL细胞表达，并且在患有高级别NHL的患者亚组中观察到MMP 9水平升高。检测158例NHL患者中MMP 2和MMP 9的表达，并分析其与临床病理因素的关系。除1例患者外，所有患者均接受了放射治疗，92例患者还接受了强化联合化疗。几乎所有结内NK/T细胞淋巴瘤鼻型和间变性大细胞淋巴瘤T细胞/空细胞型患者均表达MMP 9。相反，只有一小部分粘膜相关淋巴组织（MALT）淋巴瘤和滤泡性淋巴瘤患者表达MMP 9。大约50%的弥漫性大B细胞淋巴瘤（DLBCL）病例表达MMP 9。MMP 2在DLBCL和鼻NK/T细胞淋巴瘤中的部分表达。表达MMP 9的患者的总体生存率显著低于那些没有表达MMP 9的患者。这种相关性在MMP 2表达中未得到证实。在DLBLC患者中分析MMP 9表达时，表达MMP 9的患者的总生存率显著低于不表达MMP 9的患者。在表达MMP 9的DLBCL患者中，化疗与更好的总生存率相关。表达MMP 9的T细胞/NK细胞淋巴瘤患者的总体生存率似乎低于不表达MMP 9的患者。然而，在MMP 9表达的患者中，化疗并不能提高总生存率。在侵袭性NHL患者中观察到MMP 9表达，其特征是总体生存率低。(C)2003年美国癌症协会。
BACKGROUND. Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of tumors that vary with regard to their biologic aggressiveness and clinical course. In in vitro studies, matrix metallproteinase 9 (MMP9) was reportedly expressed by human NHL cells and elevated levels of MMP9 have been observed in a subset of patients with high-grade NHL.METHODS. The expression of MMP2 and MMP9 was evaluated in 158 patients with NHL and the relation between the expression of these proteins and clinicopathologic factors was analyzed. All but I patient had received radiation therapy and 92 log patients also were treated with intensive combination chemotherapy.RESULTS. Nearly all the patients with extranodal natural killer NK/T-cell lymphoma nasal type and anaplastic large cell lymphoma, T-cell/null cell type expressed MMP9. In contrast, only a small fraction of the patients with mucosa-associated lymphoid tissue (MALT) lymphomas and follicular lymphomas expressed MMP9. Approximately 50% of the diffuse large B-cell lymphoma (DLBCL) cases expressed MMP9. The expression of MMP2 was noted in some of the patients with DLBCL and nasal NK/T-cell lymphoma. The overall survival rates of patients who expressed MMP9 were significantly lower than that of those who did not. Such a correlation was not demonstrated in MMP2 expression. When MMP9 expression was analyzed in DLBLC patients, the overall survival rates of patients who expressed MMP9 were significantly lower than those who did not express MMP9. Chemotherapy was associated with better overall survival in DLBCL patients who expressed MMP9. Overall survival rates of T-cell/NK-cell lymphoma patients who expressed MMP9 appeared to be lower than that in those who did not ex:press MMP9. However, chemotherapy was not found to improve overall survival in patients who expressed MMP9.CONCLUSIONS. MMP9 expression was observed in patients with aggressive NHL and was characterized by poor overall survival. (C) 2003 American Cancer Society.